Genmab A/S Genmab To Hold 2023 R&D Update And Ash Data Review Meeting
December 12 2023 - 7:00AM
UK Regulatory
TIDMGEN
Media Release
-- Event to be held virtually via live webcast and archived on
www.genmab.com
Copenhagen, Denmark; December 12, 2023 --
https://www.globenewswire.com/Tracker?data=B-DdtphWiUcbM9PsOLRs1X9IQDlk_yV0wnuv4ZfoB70t-Be_bRQITKzwizHzXNWY_K7wgVAViYv62SnZlDN4QQ==
Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and ASH
Data Review Meeting today, December 12, 2023 at 11:00 AM Eastern
Time (5:00 PM CET / 4:00 PM GMT). The event will take place
virtually in English and can be attended via live webcast. To
register for the webcast, click
https://www.globenewswire.com/Tracker?data=DqYTvbQWNTkvTb2ImErIJl9H34XRLnkTmErMc7arMHcgWjIxAHUh2PfmSS2L1__bShuarOlIRjJX8pNwm1FWKQfDPLKy8ZkrYPrJdF1N5ycz2s-IU8LhtVwzKmsxfooimxOfnFENmcKo_QW1nTQDny26QmGED81JFkJVjVYZU3s=
https://genmab-post-ash-2023.open-exchange.net/. An archive of the
webcast will be available on Genmab's website.
This meeting is not an official program of the ASH Annual
Meeting.
About Genmab
Genmab is an international biotechnology company with a core
purpose guiding its unstoppable team to strive towards improving
the lives of patients through innovative and differentiated
antibody therapeutics. For more than 20 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational research
and data sciences, which has resulted in a proprietary pipeline
including bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and
antibody-drug conjugates. To help develop and deliver novel
antibody therapies to patients, Genmab has formed 20+ strategic
partnerships with biotechnology and pharmaceutical companies. By
2030, Genmab's vision is to transform the lives of people with
cancer and other serious diseases with Knock-Your-Socks-Off
(KYSO(TM)) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
https://www.globenewswire.com/Tracker?data=B-DdtphWiUcbM9PsOLRs1ceAYfdO2Rbf_eeEQIg702W_5sMdphbTR4HyZJoQBqqTzIW7gAmgiyMH_GkNh55ITQ==
Genmab.com and follow us on
https://www.globenewswire.com/Tracker?data=XOX6k4bOzAB1D5ZEkGlbaX8VnqlSHYCmu19riAYVH6OuBCN7fX5AIhAVRkcG5dZ2E3lclBrre7YREHbxZ2vHRNYf3Ffnol5DfhLAmGrH9pA=
Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications
& Corporate Affairs
T: +1 609 524 0065; E:
https://www.globenewswire.com/Tracker?data=7_exCBh3CkgMUeEFG7DtlyJHpFuf6lUz-UdABfDrHf_XRXE9VRDYMiZthP3aDHHaCwixbw7aUGaz5GUi2Jm8uw==
mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E:
https://www.globenewswire.com/Tracker?data=Sm1ojW2_WMq109bJkLYbbXIbm2FpHQVYnUBupM1vgYuQpizlSvFosxSY9KiezNO_vnhnw9vM_XO6U6thph6Oug==
acn@genmab.com
This Media Release contains forward looking statements. The
words "believe," "expect," "anticipate," "intend" and "plan" and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=9g9r64Hhi16cE87qzUmHY-EdLYH5wXAzt6RP-NtLDDtMugWZMyDHnmQ-Gf92gh_660PQegOc69Grb9FRVd1IGA==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=9g9r64Hhi16cE87qzUmHY9-eTd3w0atMmdHxbh-MuDdhZXxfTQ8KRRz0SUvaJ3EE_QilA4RDHAqXK_DCHpc5UHMQvebDPPGYYafltmoLHZc=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Media Release nor to
confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ;
HexaBody(R) ; DuoHexaBody(R) , HexElect(R) and KYSO(TM).
Media Release no. i14
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 231212_i14_Post ASH Event
https://ml-eu.globenewswire.com/Resource/Download/6e17c47e-7841-472c-9fed-19c63799d6d8
(END) Dow Jones Newswires
December 12, 2023 07:00 ET (12:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Sep 2023 to Sep 2024